Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Trinity Biotech ( (TRIB) ) has shared an announcement.
On March 10, 2026, Trinity Biotech announced significant technical advancements in its next-generation CGM+ continuous glucose monitoring platform, following more than 650 days of clinical testing on an updated sensor and electronics architecture. The enhanced system delivered materially lower Mean Absolute Relative Difference across multi-day wear, bringing performance in line with industry accuracy standards and validating the technology for progression toward regulatory submissions and scaled commercialization.
The new electronics enable multimodal sensing and AI-native analytics designed to deliver personalized metabolic health insights while supporting a modular, needle-free, user-friendly design intended to lower costs and improve sustainability versus current CGMs. Building on prior 2025 breakthroughs that removed the need for finger-stick calibration, the company is moving CGM+ into its final design phase and expects to initiate a pivotal clinical trial in 2026, positioning the device to compete in a CGM market projected to grow strongly alongside broader AI-in-healthcare and wearable AI segments.
The most recent analyst rating on (TRIB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The company is developing CGM+, a next-generation, finger-stick calibration-free continuous glucose monitoring system aimed at the fast-growing global CGM and AI-enabled digital health markets.
Average Trading Volume: 3,368,643
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.06M
Find detailed analytics on TRIB stock on TipRanks’ Stock Analysis page.